Intravitreal ranibizumab for the treatment of irvine‐gass syndrome

Abstract

AbstractPurpose The purpose of our study was to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic cystoid macular edema (CME).Methods This retrospective study comprised seven eyes with CME treated with intravitreal ranibizumab. Patients were examined at one week, one month after injection and monthly thereafter. Main outcome measures included changes in best‐corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety was assessed by ophthalmic examination and report of systemic adverse effects.Results There was a statistically significant difference on BCVA (p<0.001) and CRT (p<0.001) before and after the ranibizumab injection. One injection appeared to be sufficient for the resolution of CME, while recurrence was observed in one patient, in a long‐term follow‐up. No observable ocular or systemic side‐effects were found.Conclusion Intravitreal ranibizumab seems to be effective and safe for the treatment of pseudophakic CME, demonstrating a statistically significant difference in BCVA as well as CRT.